OCV-101 1mL will be administered by subcutaneous injection on days, 1,8,15 and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days

2 trials

Sponsors

OncoTherapy Science, Inc.

Conditions

Unresectable Advanced and Recurrent Pancreatic CancerUnresectable Advanced and Recurrent Pancreatic cancer

Phase 2

Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

Active, not recruitingJPRN-UMIN000005162

OncoTherapy Science, Inc.Unresectable Advanced and Recurrent Pancreatic Cancer

Start: 2011-03-01Target: 30Updated: 2026-06-29

Unknown Phase

Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

Active, not recruitingJPRN-UMIN000009085

OncoTherapy Science, Inc.Unresectable Advanced and Recurrent Pancreatic cancer

Start: 2012-12-01Target: 2Updated: 2026-06-29